As Boston Scientific Corp. (NYSE: BSX) plans a number of announcements in coming days at one of the largest annual cardiovascular conferences in the U.S., it’s coming off a quarterly report that shows a year-to-date net loss of more than $4 billion, and at least one stock analyst says he doubts this week’s presentations will do much to change that.